Medical Students' Exposure to and Attitudes About Drug Company Interactions

Context While exposure to and attitudes about drug company interactions amongresidents have been studied extensively, relatively little is known about relationshipsbetween drug companies and medical students.Objective Tomeasurethird-yearmedicalstudents’exposuretoandattitudesaboutdrug company interactions.Design, Setting, and Participants In 2003, we distributed a 64-item anonymoussurvey to 1143 third-year students at 8 US medical schools, exploring their exposureandresponsetodrugcompanyinteractions.Theschools’characteristicsincludedawidespectrum of ownership types, National Institutes of Health funding, and geographic lo-cations. In 2005, we conducted a national survey of student affairs deans to measurethe prevalence of school-wide policies on drug company–medical student interactions.Main Outcome Measures Monthly frequency of students’ exposure to variousactivities and gifts during clerkships, and attitudes about receiving gifts.Results Overall response rate was 826/1143 (72.3%), with range among schoolsof 30.9%-90.7%. Mean exposure for each student was 1 gift or sponsored activityper week. Of respondents, 762/818 (93.2%) were asked or required by a physicianto attend at least 1 sponsored lunch. Regarding attitudes, 556/808 (68.8%) believedgifts would not influence their practices and 464/804 (57.7%) believed gifts wouldnotaffectcolleagues’practices.Ofthestudents,553/604(80.3%)believedthattheywereentitledtogifts.Of183studentswhothoughtagiftvaluedatlessthan$50wasinappropriate, 158 (86.3%) had accepted one. The number of students who simul-taneouslybelievedthatsponsoredgrandroundsareeducationallyhelpfulandarelikelytobebiasedwas452/758(59.6%).Studentsat1schoolwhohadattendedaseminaraboutdrugcompany–physicianrelationshipswerenomorelikelythanthenonattend-ingclassmatestoshowskepticism.Oftherespondents,704/822(85.6%)didnotknowif their school had a policy on these relationships. In a national survey of student af-fairs deans, among the 99 who knew their policy status, only 10 (10.1%) reportedhaving school-wide policies about these interactions.Conclusions Student experiences and attitudes suggest that as a group they are atrisk for unrecognized influence by marketing efforts. Research should focus on evalu-ating methods to limit these experiences and affect the development of students’ at-titudes to ensure that physicians’ decisions are based solely on helping each patientachieve the greatest possible benefit.

[1]  Amy C. Brodkey The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem , 2005, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.

[2]  M. Bellin,et al.  Medical Students’ Exposure to Pharmaceutical Industry Marketing: A Survey at One U.S. Medical School , 2004, Academic medicine : journal of the Association of American Medical Colleges.

[3]  D. Blumenthal Doctors and drug companies. , 2004, The New England journal of medicine.

[4]  R. Kravitz,et al.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  T. Walley,et al.  Influences on GPs' decision to prescribe new drugs-the importance of who says what. , 2003, Family practice.

[6]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[7]  S. Peiró,et al.  Accuracy of pharmaceutical advertisements in medical journals , 2003, The Lancet.

[8]  K. Galt,et al.  Student Understanding of the Relationship Between the Health Professions and the Pharmaceutical Industry , 2003, Teaching and learning in medicine.

[9]  R. Califf,et al.  A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. , 2002, The New England journal of medicine.

[10]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[11]  A S Detsky,et al.  Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. , 2001, JAMA.

[12]  S. Mcphee,et al.  Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. , 2001, The American journal of medicine.

[13]  A. Relman,et al.  Separating continuing medical education from pharmaceutical marketing. , 2001, JAMA.

[14]  T. Bodenheimer,et al.  Uneasy alliance--clinical investigators and the pharmaceutical industry. , 2000, The New England journal of medicine.

[15]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.

[16]  David Siegel,et al.  Trends in Antihypertensive Drug Use in the United States: Do the JNC V Recommendations Affect Prescribing? , 1997 .

[17]  W. Sandberg,et al.  The Effect of Educational Gifts from Pharmaceutical Firms on Medical Students' Recall of Company Names or Products , 1997, Academic medicine : journal of the Association of American Medical Colleges.

[18]  D. Stryer,et al.  Characteristics of materials distributed by drug companies , 1996, Journal of General Internal Medicine.

[19]  W P McKinney,et al.  Physicians, pharmaceutical sales representatives, and the cost of prescribing. , 1996, Archives of family medicine.

[20]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[21]  M. Cho,et al.  The Quality of Drug Studies Published in Symposium Proceedings , 1996, Annals of Internal Medicine.

[22]  J. Berlin,et al.  When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? , 1996, Academic medicine : journal of the Association of American Medical Colleges.

[23]  B. Hodges,et al.  Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  M. Ziegler,et al.  The accuracy of drug information from pharmaceutical sales representatives. , 1995, JAMA.

[25]  M. Chren,et al.  Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. , 1994, JAMA.

[26]  D B Witzke,et al.  Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. , 1993, Annals of emergency medicine.

[27]  L. White,et al.  Pharmaceutical representatives and emergency medicine residents: a national survey. , 1993, Annals of emergency medicine.

[28]  D. Mark,et al.  The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities , 1993, Journal of General Internal Medicine.

[29]  A G Mainous,et al.  Attitudes of medical school faculty toward gifts from the pharmaceutical industry , 1992, Academic medicine : journal of the Association of American Medical Colleges.

[30]  J. Orlowski,et al.  The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. , 1992, Chest.

[31]  W P McKinney,et al.  Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. , 1990, Journal of the American Medical Association (JAMA).

[32]  Bower Ad,et al.  Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. , 1987 .

[33]  R Hartley,et al.  Scientific versus commercial sources of influence on the prescribing behavior of physicians. , 1982, The American journal of medicine.

[34]  Sebastian Schneeweiss,et al.  A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. , 2005, Journal of clinical epidemiology.

[35]  D. Vinson,et al.  Medical students' attitudes toward pharmaceutical marketing: possibilities for change. , 1993, Family medicine.

[36]  M. Bowman,et al.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education. , 1988, The Journal of continuing education in the health professions.

[37]  Marjorie A. Bowman,et al.  The impact of drug company funding on the content of continuing medical education , 1986 .

[38]  F Haayer,et al.  Rational prescribing and sources of information. , 1982, Social science & medicine.